Squamous Cell Carcinoma of Head and Neck - Immunotherapy - CDKN2A mutation

Association details:

Biomarker:	CDKN2A mutation
Cancer:	Squamous Cell Carcinoma of Head and Neck
Drug Class:	Immunotherapy
Direction:	Sensitive

Evidence:

Evidence Level:

Sensitive: C3 – Early Trials

Source:

Front Oncol

Title:

Next-generation sequencing identifies CDKN2A alterations as prognostic biomarkers in recurrent or metastatic head and neck squamous cell carcinoma predominantly receiving immune checkpoint inhibitors

Published date:

10/23/2023

Excerpt:

For the CDKN2A LOF group, the median overall survival (OS) was 16.5 months, contrasted with 30.0 months in the CDKN2A WT group (P=0.014)….Within the immunotherapy subset, the median OS was 11.7 months for the CDKN2A LOF group, and 22.5 months for the CDKN2A WT group (P=0.017)....Alterations manifesting as LOF in the CDKN2A gene stand as robust indicators of unfavorable survival outcomes in HNSCC patients, including the subset that underwent immunotherapy.

DOI:

https://doi.org/10.3389/fonc.2023.1276009